For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue from collaborations | 0 | - | ||
| Revenue from customers | 2,186 | 334 | ||
| Research and development | 69,453 | 70,269 | ||
| General and administrative | 20,718 | 22,830 | ||
| Revenue from customers | - | 3,611 | ||
| Total operating expenses | 90,171 | 93,099 | ||
| Loss from operations | -87,985 | -89,154 | ||
| Interest and other income, net | 3,922 | 4,406 | ||
| Change in fair value of 2023 common warrants | -60,184 | 46,132 | ||
| Loss before income tax | -23,879 | -130,880 | ||
| Income tax provision | 314 | 331 | ||
| Net loss | -24,193 | -131,211 | ||
| Unrealized gain on available-for-sale securities | 22 | 9 | ||
| Unrealized loss on pension plans | 5 | 103 | ||
| Other comprehensive income (loss) | 17 | -94 | ||
| Comprehensive loss | -24,176 | -131,305 | ||
| Basic EPS | -2.45 | -20.94 | ||
| Diluted EPS | -2.45 | -20.94 | ||
| Basic Average Shares | 9,884,955 | 6,264,612 | ||
| Diluted Average Shares | 9,884,955 | 6,264,612 | ||
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)